The 5 Most Interesting Analyst Questions From CNO Financial Group's Q4 Earnings Call

CNO Financial Group’s fourth quarter was marked by performance that exceeded Wall Street’s expectations, leading to a significant positive market reaction. The company’s growth was anchored by continued sales momentum across key insurance product lines, strong agent productivity, and effective diversification in product distribution channels. CEO Gary Bhojwani cited record new annualized premium, stating, “Our exclusive middle market focus and our last mile captive agent distribution model create our durable competitive moat.” Management emphasized that these operational strengths, along with disciplined investment portfolio management, underpinned both profitability and capital flexibility during the quarter.

Is now the time to buy CNO? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From CNO Financial Group’s Q4 Earnings Call

• Suneet Kamath (Jefferies) asked about the lag between writing new business and earning target returns. CFO Paul McDonough explained that returns vary by product, but guidance already captures the expected emergence of earnings from recent sales momentum.
• Suneet Kamath (Jefferies) questioned the outlook for producing agent count growth amid macro challenges. CEO Gary Bhojwani responded that agent count is expected to grow in 2026, but productivity remains the higher priority.
• Suneet Kamath (Jefferies) inquired about the pace of Bermuda reinsurance transactions. McDonough confirmed no specific plans for additional treaties in 2026, but noted the cadence should be similar to recent years.
• Wilma Jackson Burdis (Raymond James) asked if high-single-digit growth is sustainable and about the impact of Medicare Advantage changes. Bhojwani said Medicare Supplement sales should continue to grow, while other product lines could face macro-driven headwinds.
• Francis Matten (BMO Capital Markets) questioned the use of excess capital and outlook for unallocated net investment income. McDonough indicated capital deployment would remain disciplined, with a preference for share repurchases and a balanced approach to investment income volatility.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will be watching (1) whether Medicare Supplement sales sustain momentum as industry trends shift away from Medicare Advantage, (2) the impact of technology modernization investments on agent productivity and operating leverage, and (3) how macroeconomic factors influence discretionary product sales and agent recruitment. Progress on capital deployment and sustained investment portfolio performance will also be important markers of execution.

CNO Financial Group currently trades at $43.08, up from $42.31 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.